Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD

Last updated: August 16, 2025
Sponsor: Stanford University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Asperger's Disorder

Autism

Williams Syndrome

Treatment

Transcranial magnetic stimulation

Clinical Study ID

NCT04532424
IRB-57738
  • Ages 12-45
  • All Genders

Study Summary

Investigating the efficacy of a form of TMS called theta-burst stimulation for restricted and repetitive behavior in ASD.

Eligibility Criteria

Inclusion

Inclusion criteria.

  1. Diagnosis of Autism Spectrum Disorder (ASD)

  2. Meet criteria for Autism Spectrum Disorder (ASD) on clinical assessments (ADOS-2 or CARS if conducted remotely & ADI-R)

  3. Aged between 12-45 years old

  4. Have a reliable informant who can complete relevant questionnaires

  5. Have DARB scores which indicate high levels (50% or above) of RRB on one of the following domains: Insistence on Sameness, Obsessive Compulsive Behaviors, and Unusual Interests

Exclusion criteria.

  1. Any contraindications for TMS e.g. history of seizures other than clear substance-induced/fever-induced seizures with neurologist note or normal clean EEG and no seizure in at least 12 months prior to enrollment.

  2. Pregnancy.

  3. Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation.

  4. Active substance use (<1 week) or intoxication verified by toxicology screen--of cocaine, amphetamines, benzodiazepines.

  5. Showing symptoms of withdrawal from alcohol or benzodiazepines.

  6. DSM-5 diagnosis of bipolar disorder or a psychotic disorder e.g. schizophrenia.

  7. Significant sensory impairments such as blindness or deafness.

  8. Current severe insomnia (must sleep a minimum of 4 hours the night before stimulation).

  9. Not willing to cooperate with the TMS procedures.

  10. Currently taking Clozapine or another medication that the PI determines increases the risk of TMS or may disrupt the efficacy.

  11. A motor threshold that is too high to allow safe/tolerable treatment.

  12. Conditions that increase the risk for COVID-19 (in accordance with university guidelines).

Study Design

Total Participants: 67
Treatment Group(s): 1
Primary Treatment: Transcranial magnetic stimulation
Phase:
Study Start date:
January 04, 2021
Estimated Completion Date:
December 01, 2029

Connect with a study center

  • Stanford University

    Palo Alto, California 94304
    United States

    Site Not Available

  • Robin Libove

    Stanford, California 94305-5719
    United States

    Site Not Available

  • Stanford University

    Stanford, California 94305-5719
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.